GE Healthcare’s Agreement With Daiichi Sankyo

Slaughter and May advised GE Healthcare on its agreement with Daiichi Sankyo for the return of the exclusive development and marketing rights to four diagnostic imaging products in Japan to GE Healthcare and the transfer of the associated marketing authorisations.

The transfer is subject to customary regulatory approvals and closing conditions and is expected to complete in March 2020.

It is expected that Daiichi Sankyo will continue to distribute the products in Japan until March 2022 and Slaughter and May also advised on those transitional distribution arrangements.

Daiichi Sankyo is a global pharmaceutical company and the second-largest pharmaceutical company in Japan.

GE Healthcare is an American multinational conglomerate incorporated in New York and headquartered in Chicago, Illinois. As of 2017, the company is a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities that are used in medical imaging procedures.

The Slaughter and May team included Corporate/Commercial: Nilufer von Bismarck (Picture), James Cook (associate); IP/IT: Susie Middlemiss (partner), Emma Haywood (associate), Michaela Peck (associate); Tax: Emma Game (senior counsel)

Slaughter and May were supported by Nishimura & Asahi on matters of Japanese law.

Involved fees earner: James Cook – Slaughter and May; Emma Game – Slaughter and May; Emma Haywood – Slaughter and May; Susie Middlemiss – Slaughter and May; Michaela Peck – Slaughter and May; Nilufer von Bismarck – Slaughter and May;

Law Firms: Slaughter and May;

Clients: GE Healthcare;